Development of anti-p185(HER2) immunoliposomes for cancer therapy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 92, Issue 5, 1995, Pages 1327-1331

  Park, J W ^a   Hong, K ^a   Carter, P ^a   Asgari, H ^a   Guo, L Y ^a   Keller, G A ^a   Wirth, C ^a   Shalaby, R ^a   Kotts, C ^a   Wood, W I ^a   Papahadjopoulos, D ^a   Benz, C C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOLIPOSOME; LIPOSOME; MONOCLONAL ANTIBODY; GROWTH INHIBITOR; RECEPTOR, ERBB 2;

ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG COMPARISON; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG TARGETING; FEMALE; GENE EXPRESSION; INTERNALIZATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PHARMACEUTICS; PRIORITY JOURNAL; PROTO ONCOGENE; TUMOR CELL; ANIMAL; CELL CULTURE; ENDOCYTOSIS; HUMAN; IMMUNOLOGY; IN VITRO STUDY; MOUSE; MOUSE MUTANT;

ANIMALIA;

ANIMAL; ANTIBODIES, MONOCLONAL; DOXORUBICIN; ENDOCYTOSIS; FEMALE; GROWTH INHIBITORS; HUMAN; IN VITRO; LIPOSOMES; MICE; MICE, SCID; RECEPTOR, ERBB-2; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED;

EID: 0028986610     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.92.5.1327     Document Type: Article

References (0)